ELISA/assay

Canine Cystatin C ELISA Kit

MBS738091

48-Strip-Wells

470 USD

ELISA Kit

Canine Cystatin C ELISA Kit

Cystatin C

cystatin-C; Cystatin-C; cystatin-C; cystatin 3; cystatin-3; gamma-trace; post-gamma-globulin; bA218C14.4 (cystatin C); neuroendocrine basic polypeptide; cystatin C; Cystatin-3; Gamma-trace; Neuroendocrine basic polypeptide; Post-gamma-globulin

Cys-C

CST3; CST3; ARMD11

CYTC_HUMAN

Canine

This assay has high sensitivity and excellent specificity for detection of Cys-C. No significant cross-reactivity or interference between Cys-C and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between Cys-C and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 1.0 ng/mL.

Intended Uses: This Cys-C ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Canine Cys-C. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cell Biology

Principle of the assay: Cys-C ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-Cys-C antibody and an Cys-C-HRP conjugate. The assay sample and buffer are incubated together with Cys-C-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the Cys-C concentration since Cys-C from samples and Cys-C-HRP conjugate compete for the anti-Cys-C antibody binding site. Since the number of sites is limited, as more sites are occupied by Cys-C from the sample, fewer sites are left to bind Cys-C-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The Cys-C concentration in each sample is interpolated from this standard curve.

4503107

NP_000090.1

NM_000099.3

15,799 Da

Amyloids Pathway (366238); Disease Pathway (530764); Integrated Pancreatic Cancer Pathway (711360); Salivary Secretion Pathway (153376); Salivary Secretion Pathway (153352)

The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes the most abundant extracellular inhibitor of cysteine proteases, which is found in high concentrations in biological fluids and is expressed in virtually all organs of the body. A mutation in this gene has been associated with amyloid angiopathy. Expression of this protein in vascular wall smooth muscle cells is severely reduced in both atherosclerotic and aneurysmal aortic lesions, establishing its role in vascular disease. Alternative splicing results in multiple transcript variants encoding a single protein. [provided by RefSeq, Dec 2013]

CST3: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Defects in CST3 are the cause of amyloidosis type 6 (AMYL6); also known as hereditary cerebral hemorrhage with amyloidosis (HCHWA), cerebral amyloid angiopathy (CAA) or cerebroarterial amyloidosis Icelandic type. AMYL6 is a hereditary generalized amyloidosis due to cystatin C amyloid deposition. Cystatin C amyloid accumulates in the walls of arteries, arterioles, and sometimes capillaries and veins of the brain, and in various organs including lymphoid tissue, spleen, salivary glands, and seminal vesicles. Amyloid deposition in the cerebral vessels results in cerebral amyloid angiopathy, cerebral hemorrhage and premature stroke. Cystatin C levels in the cerebrospinal fluid are abnormally low. Genetic variations in CST3 are associated with age- related macular degeneration type 11 (ARMD11). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Belongs to the cystatin family. Protein type: Inhibitor; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 20p11.21. Cellular Component: extracellular space; extracellular region. Molecular Function: protein binding; protease binding; beta-amyloid binding; endopeptidase inhibitor activity; cysteine protease inhibitor activity. Biological Process: negative regulation of proteolysis; fibril organization and biogenesis; negative regulation of peptidase activity; defense response; regulation of tissue remodeling. Disease: Macular Degeneration, Age-related, 11; Cerebral Amyloid Angiopathy, Cst3-related

48-Strip-Wells

470 USD

96-Strip-Wells

675